Article
FR171456 is a specific inhibitor of mammalian NSDHL and yeast Erg26p.
Nature communications - 12 Oct 2015
Helliwell Stephen B, Karkare Shantanu, Bergdoll Marc, Rahier Alain, Leighton-Davis Juliet R, Fioretto Celine, Aust Thomas, Filipuzzi Ireos, Frederiksen Mathias, Gounarides John, Hoepfner Dominic, Hofmann Andreas, Imbert Pierre-Eloi, Jeker Rolf, Knochenmuss Richard, Krastel Philipp, Margerit Anais, Memmert Klaus, Miault Charlotte V, Rao Movva N, Muller Alban, Naegeli Hans-Ulrich, Oberer Lukas, Prindle Vivian, Riedl Ralph, Schuierer Sven, Sexton Jessica A, Tao Jianshi, Wagner Trixie, Yin Hong, Zhang Juan, Roggo Silvio, Reinker Stefan, Parker Christian N
Abstract excerpt
FR171456 is a natural product with cholesterol-lowering properties in animal models, but its molecular target is unknown, which hinders further drug development. Here we show that FR171456 specifically targets the sterol-4-alpha-carboxylate-3-dehydrogenase (Saccharomyces cerevisiae--Erg26p, Homo sapiens--NSDHL (NAD(P) dependent steroid dehydrogenase-like)), an essential enzyme in the ergosterol/cholesterol...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
